In the face of looming revenue decline from blood cancer medication Revlimid, Indian pharma companies Natco Pharma and Dr.

Natco Pharma stock corrected sharply due to weak Q3 results, but future opportunities like semaglutide offer hope.

Natco Pharma plans to launch its CTPR products very shortly, which is estimated to have a market size of over ₹2,000 crore in India. Natco Pharma shares surged after the drug maker unveiled the first ...

Lupin and Natco receive US FDA approval for generic Tracleer tablets for oral suspension: Our Bureau, Mumbai Monday, February 10, 2025, 15:45 Hrs [IST] Global pharma major Lupin L ...

Natco Pharma has received U.S. Food and Drug Administration final approval for Bosentan tablets for oral suspension, 32mg, its generic version of Actelion Pharmaceuticals US Inc.’s pulmonary ...

During the quarter, contribution from the export formulation business was lower; however, the company expects healthy ...

Hyderabad: NATCO Pharma Limited has announced final approval of its Abbreviated New Drug Application (ANDA) for Bosentan ...

The company had posted a consolidated net profit of Rs 212.7 crore in the third quarter of the previous fiscal year, NATCO Pharma said in a regulatory filing. Consolidated revenue from operations in ...

Shares of NATCO Pharma tumbled another 10% in intra-day trade on Friday, February 14, extending its slide to the sixth straight session. The stock had tumbled 20% on Thursday as well following the ...

Natco Pharma Ltd. is a Public Limited Listed ... medicinal chemical and botanical products. Company's Total Operating Revenue is Rs. 3568.90 Cr. and Equity Capital is Rs. 35.80 Cr.

Natco Pharma Ltd shares tanked during the early trading session on Thursday, February 13, 2025, after it announced weak third quarter financial results. Natco Pharma Ltd. shares tanked during the ...